SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma

Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.

Share this video  
12th June 2015